地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:18771997407
传真:18771997407
邮箱:sales@amyjet.com

KENOSHA is the only truly specialized and independent provider of adhesive materials and related services to IVD and Medical Device manufacturers.
KENOSHA的主要产品包括:
(1)Lateral Flow
Backing Cards and Cover Tapes
Backing Cards Starter Kit
Conjugation Kits
(2)Medical Device
Medical Device Protective Packaging
Woundcare Adhesives
Filtration Media
Biosensor Films & Laminates
Medical Grade Adhesives
Microtiter Plate Sealing Tapes
IVD Trade
(3)Microfluidics
Microfluidic R2R
Paper-based Diagnostic Devices
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
" data-original="http://bioauxilium.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="KENOSHA"> KENOSHA
艾美捷科技特约代理Biogems产品。
BioGems意为生物钻石,其产品涵盖多种荧光标记的流式抗体、具有生物活性的功能性抗体,以及流式细胞术辅助试剂,如溶血剂和破膜剂等。BioGems产品全部在美国生产,目前已拥有超过500种流式试剂和600余种重组蛋白产品。
Through the establishment of joint collaborations with reputable manufacturers of top-quality life-science research products such as PeproTech Inc., BioGems has positioned itself to become a highly competitive source for a wide-range of recombinant protein and flow-cytometry reagents. Currently, our catalog contains more than 600 recombinant proteins and over 500 flow cytometry reagents. To keep up with the rapidly advancing research fronts, BioGems continuously adds new products to its catalog. All of our products are subjected to a thorough and rigorous quality and performance testing to ensure that each and every product meets the highest established standards. Providing our customers with the highest-quality products at affordable prices is our goal. We are confident that the unique business arrangements of BioGems together with our highly skilled and experienced personnel will enable us to achieve this goal.
主要产品分类:
(1)Flow Cytometry
Conjugated Antibodies
SAFIRE Functional Antibodies
Isotype Controls
Custom and Bulk Reagents
Purified Antibodies
Buffers and Solutions
(2)Recombinant Proteins
Growth Factors & Cytokines
Animal-Free Cytokines
Chemokines
Neurotrophins
Other Proteins
Anti Cytokine & Chemokine Antibodies
(3)Small Molecules
Receptor Antagonist and Inhibitors
Receptor Agonists and Activators
(4)Pre-Coated Elisa Kits
Human
Mouse
Rat
" data-original="http://bioauxilium.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="BioGems"> BioGems
艾美捷科技特约代理Athens Research & Technology产品。
Athens Research & Technology公司位于美国乔治亚州雅典市,从1986年以来一直致力于纯化高纯度,高活性的人类蛋白质和开发这些蛋白的多克隆抗血清。常规产品包括丝氨酸蛋白酶、蛋白酶抑制剂、中性粒细胞酶、载脂蛋白、脂蛋白,血小板蛋白、转铁蛋白、免疫球蛋白等。
Athens Research & Technology Inc. has been purifying human proteins and developing polyclonal antisera to those proteins since 1986. We specialize in highly pure, highly active human proteins. We routinely purify serine proteases, protease inhibitors, neutrophil enzymes, apolipoproteins, lipoproteins, platelet proteins, transferrins, immunoglobulins, and more. Researchers around the world have been purchasing these research reagents from us for more than twenty-five years. You'll see our products referenced in major scientific publications in studies of inflammation, coronary disease, autoimmune disease, cancer, Alzheimer's Disease, and so on.
Athens Research & Technology公司的主要产品包括:
Coagulation Factors
Enzymes & Inhibitors
Immunoglobulins
Lipoproteins & Apolipoproteins
Low Endotoxin Level Proteins
Milk & Platelet Proteins
Neutrophil Proteins
Transferrins & Apotransferrins
Transport/Other Proteins
All Human Proteins
All Animal Proteins
Antibodies
Assay Kits
" data-original="http://bioauxilium.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Athens Research & Technology"> Athens Research & Technology
Premetek公司致力于为学术客户和工业客户提供化学试剂、纳米材料和催化剂,同时也提供多领域的研发服务。通过不断地与业内专业企业进行技术整合,Premetek不断更新产品,并为材料科学和催化领域提供了最多样化和可扩展的选择。
Our retail objectives are to offer the most expansive selection of premium products, provide easy and friendly service, offer the fastest delivery time possible, and ensure that every customer is satisfied with their purchase. Our inventory is determined by extensive market research, attendance at international tradeshows and conferences, customer feedback, and working closely with industry experts and vendors. Premetek is committed to continually improving our services and being the premier online market place for all your needs.
Premetek公司的主要产品包括:
Nanomaterials
Nanomaterial Suspension
Pt,Pd Catalysts -Hydrogenation
Pt,Pd Catalysts -Red/Oxidation
Pt Catalysts - Electrochemistry
Pt Alloy Catalysts - Electrochemistry
Pd Alloy Catalysts - Electrochemistry
Pd,Ru,Ir,Rh,Au Catalysts - Electrochemistry
Fe,Co,Ni,Cu,Ag Catalysts - Electrochemistry
Pt,Pd,Ru,Ir,Rh,Au-Organometallics
Pt, Pd, Rh Homogeneous Catalysts
Custom Products
Special catalysts in stock
| 品名 | 货号 | 规格 |
| Aluminum titanate, Al2TiO5, 40 g each | N10A1000 | 40g |
| Barium strontium titanium oxide, BaSrTi2O6, 40 g each | N10B2000 | 40g |
| Calcium titanate, CaTiO3, 40 g each | N10C1000 | 40g |
| Calcium zirconium titanium oxide, CaZrTi2O3, 40 g each | N10C2000 | 40g |
| Cadmium tungsten oxide, CdWO4, 40 g each | N10C3000 | 40g |
| Cerium aluminate, CeAlO3, 40 g each | N10C4000 | 40g |
| Copper aluminate, CuAl2O4, 40 g each | N10C5000 | 40g |
| Iron nickel oxide, FeNiO4, 40 g each | N10I1000 | 40g |
| Lanthanum chromite, LaCrO3, 40 g each | N10L1000 | 40g |
| Lanthanum manganite , LaMnO3, 40 g each | N10L3000 | 40g |
| Lanthanum substituted lithium titanate, (LaLi3)TiO3, 40 g each | N10L5000 | 40g |
| Lead zirconium substituted titanate, PbZr0.2Ti0.8O3, 40 g each | N10L6000 | 40g |
| Manganese titanate, MnTiO3, 40 g each | N10M1000 | 40g |
| Magnesium aluminate, MgAl2O4, 40 g each | N10M2000 | 40g |
| Nickel cobalt oxide, NiCoO2, 40 g each | N10N1000 | 40g |
| Strontium bismuth niobium oxide, SrBi2Nb2O9, 50 g each | N10S1000 | 40g |
| Strontium ferrite, SrFe12O19, 40 g each | N10S2000 | 40g |
| Yttrium aluminum oxide, Y3Al5O12, 40 g each | N10Y1000 | 40g |
| Yttrium iron oxide, Y3Fe5O12, 40 g each | N10Y2000 | 40g |
| Zinc iron oxide, ZnFe2O4, 40 g each | N10Z1000 | 40g |
| Zinc titanium oxide, ZnTiO3, 40 g each | N10Z2000 | 40g |
| Concentrated Suspension of Nanoscaled Titanium Dioxide (TiO2), 5 kg | N-1000 | 5kg |
| Concentrated Suspension of Nanoscaled Zinc Oxide (ZnO), 5 kg | N-2000 | 5kg |
| Concentrated Suspension of Nanoscaled Zinc Oxide (ZnO), 5 kg | N-2010 | 5kg |
| Suspension of Nanoscaled Iron Oxide (Fe2O3), 5 kg | N-3000 | 5kg |
| Concentrated Suspension of Nanoscaled Iron Oxide (Fe2O3), 5 kg | N-3010 | 5kg |
| Concentrated Suspension of Nanoscaled Iron Oxide (Fe2O3), 5 kg | N-3020 | 5kg |
| Concentrated Suspension of Nanoscaled Iron Oxide (Fe2O3), 5 kg | N-3130 | 5kg |
| Concentrated Suspension of Nanoscaled Iron Oxide (Fe2O3), 5 kg | N-3220 | 5kg |
| Concentrated Suspension of Nanoscaled Iron Oxide (Fe2O3), 5 kg | N-3230 | 5kg |
| 0.1% Pt on activated carbon powder, 10 g each | P10J1001 | 10g |
| 0.5% Pt on activated carbon powder, 10 g each | P10J1005 | 10g |
| 1.0% Pt on activated carbon powder, 10 g each | P10J1010 | 10g |
| 5.0% Pt on activated carbon powder, 10 g each | P10J1050 | 10g |
| 10% Pt on activated carbon powder, 10 g each | P10J1100 | 10g |
| 20% Pt on activated carbon powder, 10 g each | P10J1200 | 10g |
| 0.1% Pt on granular carbon, 10 g each | P10J2001 | 10g |
| 0.5% Pt on granular carbon, 10 g each | P10J2005 | 10g |
| 1.0% Pt on granular carbon, 10 g each | P10J2010 | 10g |
| 5.0% Pt on granular carbon, 10 g each | P10J2050 | 10g |
| 0.1% Pd on activated carbon powder, 10 g each | P30J1001 | 10g |
| 0.5% Pd on activated carbon powder, 10 g each | P30J1005 | 10g |
| 1.0% Pd on activated carbon powder, 10 g each | P30J1010 | 10g |
| 5.0% Pd on activated carbon powder, 10 g each | P30J1050 | 10g |
| 10% Pd on activated carbon powder, 10 g each | P30J1100 | 10g |
| 20% Pd on activated carbon powder, 10 g each | P30J1200 | 10g |
| 0.1% Pd on granular carbon, 10 g each | P30J2001 | 10g |
| 0.3% Pd on granular carbon, 10 g each | P30J2003 | 10g |
| 0.5% Pd on granular carbon, 10 g each | P30J2005 | 10g |
| 1.0% Pd on granular carbon, 10 g each | P30J2010 | 10g |
| 5.0% Pd on granular carbon, 10 g each | P30J2050 | 10g |
| 0.5% Pd on alumina spheres, 3 mm, SA= | P30L1005 | 10g |
| 1.0% Pd on alumina spheres, 3 mm, SA= | P30L1010 | 10g |
| 0.1% Pt on alumina powder, 10 g each | P10K1001 | 10g |
| 0.5% Pt on alumina powder, 10 g each | P10K1005 | 10g |
| 1.0% Pt on alumina powder, 10 g each | P10K1010 | 10g |
| 5.0% Pt on alumina powder, 10 g each | P10K1050 | 10g |
| 10% Pt on alumina powder, 10 g each | P10K1100 | 10g |
| 20% Pt on alumina powder, 10 g each | P10K1200 | 10g |
| 0.1% Pd on alumina powder, 10 g each | P30K1001 | 10g |
| 0.5% Pd on alumina powder, 10 g each | P30K1005 | 10g |
| 1.0% Pd on alumina powder, 10 g each | P30K1010 | 10g |
| 5.0% Pd on alumina powder, 10 g each | P30K1050 | 10g |
| 10% Pd on alumina powder, 10 g each | P30K1100 | 10g |
| 20% Pd on alumina powder, 10 g each | P30K1200 | 10g |
| 5% Pt on Vulcan XC-72 | P10A050 | 1g/5g |
| 10% Pt on Vulcan XC-72 | P10A100 | 1g/5g |
| 20% Pt on Vulcan XC-72 | P10A200 | 1g/5g |
| 30% Pt on Vulcan XC-72 | P10A300 | 1g/5g |
| 40% Pt on Vulcan XC-72 | P10A400 | 1g/5g |
| 50% Pt on Vulcan XC-72 | P10A500 | 1g/5g |
| 60% Pt on Vulcan XC-72 | P10A600 | 1g/5g |
| 80% Pt on Vulcan XC-72 | P10A800 | 1g/5g |
| Pt Black, High surface area: 40-50 m2/g, Low density: 0.6-0.9 g/ml | P10V010 | 1g/5g |
| 20% Pt on Durable Carbon | P10D200 | 1g/5g |
| 20% Pt on Vulcan XC-72R | P10B200 | 1g/5g |
| 40% Pt on Vulcan XC-72R | P10B400 | 1g/5g |
| 60% Pt on Vulcan XC-72R | P10B600 | 1g/5g |
| 40% Pt on high surface area Ketjenblack | P10E400 | 1g/5g |
| 50% Pt on high surface area Ketjenblack, | P10E500 | 1g/5g |
| 60% Pt on high surface area Ketjenblack | P10E600 | 1g/5g |
| 70% Pt on high surface area Ketjenblack | P10E700 | 1g/5g |
| 5% Pt-Ru (1:1 atomic ratio) on Vulcan XC-72 | P12A050 | 1g/5g |
| 10% Pt-Ru (1:1 atomic ratio) on Vulcan XC-72 | P12A100 | 1g/5g |
| 20% Pt-Ru (1:1 atomic ratio) on Vulcan XC-72 | P12A200 | 1g/5g |
| 30% Pt-Ru (1:1 atomic ratio) on Vulcan XC-72 | P12A300 | 1g/5g |
| 40% Pt-Ru (1:1 atomic ratio) on Vulcan XC-72 | P12A400 | 1g/5g |
| 50% Pt-Ru (1:1 atomic ratio) on Vulcan XC-72 | P12A500 | 1g/5g |
| 60% Pt-Ru (1:1 atomic ratio) on Vulcan XC-72R | P12B600 | 1g/5g |
| 60% Pt-Ru (1:1 atomic ratio) on Vulcan XC-72 | P12A600 | 1g/5g |
| 80% Pt-Ru (1:1 atomic ratio) on Vulcan XC-72 | P12A800 | 1g/5g |
| Pt-Ru Black (1:1 atomic ratio) | P12V010 | 1g/5g |
| Pt-Ru Black (2.5:1 atomic ratio) | P12V250 | 1g/5g |
| Pt-Ru-Ir Black (1:1:1 atomic ratio) | P124V010 | 1g/5g |
| 50% Pt-Ru (1:1 atomic ratio) on Ketjenblack | P12E500 | 1g/5g |
| 60% Pt-Ru (1:1 atomic ratio) on Ketjenblack | P12E600 | 1g/5g |
| 75% Pt-Ru (1:1 atomic ratio) on Ketjenblack | P12E750 | 1g/5g |
| 20% Pt-Pd (1:3 atomic ratio) on Vulcan XC-72 | P13A203 | 1g/5g |
| 20% Pt-Pd (1:1 atomic ratio) on Vulcan XC-72 | P13A200 | 1g/5g |
| 20% Pt-Pd (3:1 atomic ratio) on Vulcan XC-72 | P13A230 | 1g/5g |
| 40% Pt-Pd (1:1 atomic ratio) on Vulcan XC-72 | P13A400 | 1g/5g |
| Pt-Pd Black (1:1 atomic ratio) | P13V010 | 1g/5g |
| Pt-Rh Black (1:1 atomic ratio) | P15V010 | 1g/5g |
| 20% Pt-Ir (1:3 atomic ratio) on Vulcan XC-72 | P14A203 | 1g/5g |
| 20% Pt-Ir (1:1 atomic ratio) on Vulcan XC-72 | P14A200 | 1g/5g |
| 20% Pt-Ir (3:1 atomic ratio) on Vulcan XC-72 | P14A230 | 1g/5g |
| 40% Pt-Ir (1:1 atomic ratio) on Vulcan XC-72 | P14A400 | 1g/5g |
| Pt-Ir Black (1:1 atomic ratio) | P14V010 | 1g/5g |
| 20% Pt-Cr (3:1 atomic ratio) on Vulcan XC-72 | P1AA230 | 1g/5g |
| 40% Pt-Cr (3:1 atomic ratio) on Vulcan XC-72 | P1AA430 | 1g/5g |
| 20% Pt-Fe (1:1 atomic ratio) on Vulcan XC-72 | P1BA200 | 1g/5g |
| 40% Pt-Fe (1:1 atomic ratio) on Vulcan XC-72 | P1BA400 | 1g/5g |
| 40% Pt-Fe (3:1 atomic ratio) on Vulcan XC-72 | P1BA430 | 1g/5g |
| 20% Pt-Co (1:1 atomic ratio) on Vulcan XC-72 | P1CA200 | 1g/5g |
| 20% Pt-Co (3:1 atomic ratio) on Vulcan XC-72 | P1CA230 | 1g/5g |
| 40% Pt-Co (1:1 atomic ratio) on Vulcan XC-72 | P1CA400 | 1g/5g |
| 40% Pt-Co (3:1 atomic ratio) on Vulcan XC-72 | P1CA430 | 1g/5g |
| 60% Pt-Co (3:1 atomic ratio) on Ketjenblack | P1CE630 | 1g/5g |
| 20% Pt-Ni (1:1 atomic ratio) on Vulcan XC-72 | P1DA200 | 1g/5g |
| 20% Pt-Ni (3:1 atomic ratio) on Vulcan XC-72 | P1DA230 | 1g/5g |
| 40% Pt-Ni (1:1 atomic ratio) on Vulcan XC-72 | P1DA400 | 1g/5g |
| 40% Pt-Ni (3:1 atomic ratio) on Vulcan XC-72 | P1DA430 | 1g/5g |
| 60% Pt-Ni (3:1 atomic ratio) on Ketjenblack | P1DE630 | 1g/5g |
| 20% Pt-Cu (1:1 atomic ratio) on Vulcan XC-72 | P1EA200 | 1g/5g |
| 20% Pt-Cu (3:1 atomic ratio) on Vulcan XC-72 | P1EA230 | 1g/5g |
| 20% Pt-Sn (3:1 atomic ratio) on Vulcan XC-72 | P1FA230 | 1g/5g |
| 40% Pt-Sn (3:1 atomic ratio) on Vulcan XC-72 | P1FA430 | 1g/5g |
| 20% Pd-Ir (1:3 atomic ratio) on Vulcan XC-72 | P34A203 | 1g/5g |
| 20% Pd-Ir (1:1 atomic ratio) on Vulcan XC-72 | P34A200 | 1g/5g |
| 20% Pd-Ir (3:1 atomic ratio) on Vulcan XC-72 | P34A230 | 1g/5g |
| 20% Pd-Rh (1:1 atomic ratio) on Vulcan XC-72 | P35A200 | 1g/5g |
| 20% Pd-Rh (3:1 atomic ratio) on Vulcan XC-72 | P35A230 | 1g/5g |
| 20% Pd-Ni (1:1 atomic ratio) on Vulcan XC-72 | P3DA200 | 1g/5g |
| 40% Pd-Au (1:1 atomic ratio) on Ketjenblack | P13E400 | 1g/5g |
| 5% Pd on Vulcan XC-72 | P30A050 | 1g/5g |
| 10% Pd on Vulcan XC-72 | P30A100 | 1g/5g |
| 20% Pd on Vulcan XC-72 | P30A200 | 1g/5g |
| 40% Pd on Vulcan XC-72 | P30A400 | 1g/5g |
| 40% Pd on Ketjenblack | P30E400 | 1g/5g |
| 60% Pd on Vulcan XC-72 | P30A600 | 1g/5g |
| 80% Pd on Vulcan XC-72 | P30A800 | 1g/5g |
| Pd Black, High surface area 40~48 m2/g | P30V010 | 1g/5g |
| 20% Ru on Vulcan XC-72 | P20A200 | 1g/5g |
| 40% Ru on Vulcan XC-72, | P20A400 | 1g/5g |
| Ru Black, High surface area 38~48 m2/g | P20V010 | 1g/5g |
| RuO2 powder, Surface area 18-25 m2/g | P20V020 | 1g/5g |
| 5% Ir on Vulcan XC-72 | P40A050 | 1g/5g |
| 10% Ir on Vulcan XC-72 | P40A100 | 1g/5g |
| 20% Ir on Vulcan XC-72 | P40A200 | 1g/5g |
| 40% Ir on Vulcan XC-72 | P40A400 | 1g/5g |
| Ir Black, High Surface area, 55~65 m2/g, | P40V010 | 1g/5g |
| IrOx powder, conductive, SA:10-20 m2/g | P40V020 | 1g/5g |
| Ru-Ir Black (1:1 atomic ratio) | P24V010 | 1g/5g |
| 20% Rh on Vulcan XC-72 | P50A200 | 1g/5g |
| Rh Black, High surface area 40~50 m2/g | P50V010 | 1g/5g |
| 20% Au on Vulcan XC-72 (Au particle size: 4-8 nm) | P60N200 | 1g/5g |
| 20% Au on Vulcan XC-72 (Au particle size: ~25 nm) | P60A200 | 1g/5g |
| 30% Au on Vulcan XC-72 (Au particle size: 8 nm) | P60N300 | 1g/5g |
| 40% Au on Vulcan XC-72 (Au particle size: ~35 nm) | P60A400 | 1g/5g |
| 40% Au on Ketjenblack (Au particle size: 4 nm) | P60E400 | 1g/5g |
| 60% Au on Vulcan XC-72 (Au particle size: ~45 nm) | P60A600 | 1g/5g |
| 5% Fe on Vulcan XC-72 | T10A050 | 1g/5g |
| 10% Fe on Vulcan XC-72 | T10A100 | 1g/5g |
| 20% Fe on Vulcan XC-72 | T10A200 | 1g/5g |
| 1% Co on Vulcan XC-72 | T20A010 | 1g/5g |
| 5% Co on Vulcan XC-72 | T20A050 | 1g/5g |
| 10% Co on Vulcan XC-72 | T20A100 | 1g/5g |
| 20% Co on Vulcan XC-72 | T20A200 | 1g/5g |
| 1% Ni on Vulcan XC-72 | T30A010 | 1g/5g |
| 5% Ni on Vulcan XC-72 | T30A050 | 1g/5g |
| 10% Ni on Vulcan XC-72 | T30A100 | 1g/5g |
| 20% Ni on Vulcan XC-72 | T30A200 | 1g/5g |
| 40% Ni on Vulcan XC-72 | T30A400 | 1g/5g |
| 1% Cu on Vulcan XC-72 | T40A010 | 1g/5g |
| 5% Cu on Vulcan XC-72 | T40A050 | 1g/5g |
| 10% Cu on Vulcan XC-72 | T40A100 | 1g/5g |
| 20% Cu on Vulcan XC-72 | T40A200 | 1g/5g |
| 40% Cu on Vulcan XC-72 | T40A400 | 1g/5g |
| 60% Cu on Vulcan XC-72 | T40A600 | 1g/5g |
| 20% Ag on Vulcan XC-72 | P70A200 | 1g/5g |
| 40% Ag on Vulcan XC-72 | P70A400 | 1g/5g |
| 60% Ag on Vulcan XC-72 | P70A600 | 1g/5g |
| 80% Ag on Vulcan XC-72 | P70A800 | 1g/5g |
| Platinum (II) acetylacetonate, 5 g each | P10H110 | 5g |
| (1,5-Cyclooctadiene)dimethylplatinum(II), 1 g each | P10H120 | 1g |
| Dichloro(1,5-cyclooctadiene)platinum(II), 5 g each | P10H130 | 5g |
| Diphenyl(1,5-cyclooctadiene)platinum(II), 5 g each | P10H140 | 5g |
| Trimethylbenzylammoniumhexachloroplatinate (IV), 1 g each | P10H150 | 1g |
| Palladium(II) acetylacetonate, 5 g each | P30H110 | 5g |
| Dichloro(1,5-cyclooctadiene)palladium(II), 5 g each | P30H120 | 5g |
| Hermann's Catalyst, 5 g each | P30H130 | 5g |
| 1,1'-Bis(di-tert-butylphosphino)ferrocene palladium dichloride, 1 g each | P30H140 | 1g |
| Bis(dibenzylideneacetone)palladium(0), 5 g each | P30H150 | 5g |
| Palladium(0) tetrakis(triphenylphosphine), 5 g each | P30H160 | 5g |
| Ruthenium(III) acetylacetonate, 5 g each | P20H110 | 5g |
| Dichloro(1,5-cyclooctadiene)ruthenium(II), polymer, 5 g each | P20H120 | 5g |
| Bis(cyclopentadienyl)ruthenium, 5 g each | P20H130 | 5g |
| Irridium(III) acetylacetonate, 5 g each | P40H110 | 5g |
| Chloro(1,5-cyclooctadiene)iridium(I) dimer, 5 g each | P40H120 | 5g |
| Rhodium(III) acetylacetonate, 5 g each | P50H110 | 5g |
| Chloro(1,5-cyclooctadiene)rhodium(I) dimer, 1 g each | P50H120 | 1g |
| Chloro(triphenylphosphine)gold(I), 5 g each | newitem3 | 5g |
| Bromo(triphenylphosphine)gold(I), 5 g each | P60H110 | 5g |
| Chloro(1,5-cyclooctadiene)rhodium(I) dimer, 98% 1 g | P50-002 | 1g |
| Chloro(1,5-cyclooctadiene)rhodium(I) dimer, 98% 1 g | P50-002 | 1g |
| Doyledirhodium catalyst-Rh2(5R-MPPIM)4, 1 g | P50-001 | 1g |
| Doyledirhodium catalyst-Rh2(5S-MPPIM)4, 1 g | P50-003 | 1g |
更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com

艾美捷科技代理Polysciences品牌。
Polysciences的产品以其高质量和多样性而著称,特别是在聚乙烯亚胺(Polyethylenimine,PEI)转染试剂方面有着显著的优势。Polysciences公司成立于1961年,主要生产和经营生命科学(胶体金、不含甲醛的甲醇等)、病理学和显镜学微球和粒子、磁珠、各种单体和聚体等产品;作为世界上最大最全的多聚化合物供应商,同时也是世界领先的免疫学、组织化学试剂耗材供应商。
Polysciences特色的PEI转染试剂特点包括:
(1)高效性:PEI转染试剂具有高效的瞬转效率和蛋白产量,广泛应用于基因和细胞治疗产品的开发,包括病毒载体和蛋白质工艺开发、临床试验以及商业化生产。
(2)广泛适用性:适用于多种细胞系,如HEK293、CHO、Sf9等,且转染效率高达80%~90%。
(3)升级产品:如PEI MAX 40K,作为第一代PEI 25K的升级产品,其去乙酰化和盐酸盐形式增强了水溶性,提高了转染效率。
产品应用范围包括:
病毒载体开发:可用于生产和优化病毒载体,将基因修饰的病毒载体导入目标细胞内,从而实现基因转染;
重组蛋白表达:可以将编码目标蛋白的基因高效地转入宿主细胞,从而大量表达所需的重组蛋白;
基因编辑技术:如CRISPR-Cas9系统中,PEI转染试剂用于将相关基因编辑组件送入细胞内;
细胞治疗研究:用于提高细胞的治疗效果和生存率,需要将特定的遗传物质传递到细胞内,以改变细胞的行为或增强其治疗效果。
<<<< " data-original="http://bioauxilium.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Polysciences品牌转染试剂"> 艾美捷科技代理Polysciences品牌转染试剂

艾美捷科技代理Berry & Associates全系列修饰核苷酸等
美国 Berry & Associates 公司成立于1989年,提供近200种亚磷酰胺和核苷酸合成用固相交联单体,以及数百种核苷、核苷酸、糖类、荧光标记物、淬灭剂和杂环化合物。
Founded in 1989 with roots in the nucleoside field, Berry & Associates soon moved into the chemistry of nucleic acids, resulting in a current portfolio of nearly 200 phosphoramidites and solid phase-linked monomers for oligonucleotide synthesis as well as hundreds of nucleosides, nucleotides, carbohydrates, spacers, fluorescent markers, quenchers, and heterocycles - all proudly made at our facility just outside of Ann Arbor, Michigan. Although our company is small, the credentials of our highly trained staff of chemists include over 400 publications and 80 patents in synthetic organic and medicinal chemistry. High quality chemicals, timeliness, and personalized service are the hallmarks of Berry & Associates.







Berry & Associates的主要产品包括:
| 产品名称 | 产品编号 | 纯度 | 规格 |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2'-3'-Dideoxyguanosine | PR 3505 | ≥95% | 25 mg; 100 mg |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 2',3'-Dideoxyuridine | PY 7278 | ≥97% | 100 mg; 500 mg |
| 2',3'-Didehydro-2',3'-dideoxyuridine | PY 7279 | ≥97% | 25 mg; 100 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| 2-Amino-2'-deoxyadenosine | PR 3060 | ≥97% | 1 g; 5 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-deoxyadenosine | PR 3080 | ≥95% | 100 mg; 1 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-isobutyryl-2'-deoxyadenosine | PR 3130 | ≥95% | 100 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2-(Dimethylaminomethylidene)amino-6-methoxylamino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3670 | ≥95% | 100 mg; 1 g |
| 2-Amino-9-(β-D-2'-deoxyribfuranosyl)purine | PR 3070 | ≥97% | 25 mg; 100 mg |
| 2-Amino-9-(2-O-methyl-β-D-ribofuranosyl)purine | PR 3160 | ≥97% | 100 mg; 250 mg |
| 2-Amino-9-(β-D-ribofuranosy)purine Hemihydrate | PR 3180 | ≥97% | 25 mg; 100 mg |
| 2-(Dimethylaminomethylidene)amino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3680 | ≥97% | 100 mg; 1 g |
| 6-N-Acyl-6-N-methyl-2'-deoxyadenosine | PR 3006 | ≥95% | 25 mg; 100 mg |
| 8-Amino-2'-deoxyadenosine | PR 3115 | ≥97% | 10 mg; 100 mg |
| N6-(6-Aminohexyl)-2'-deoxyadenosine | PR 3120 | ≥90% | 100 mg; 1 g |
| 8-Azido-2'-deoxyadenosine | PR 3125 | ≥97% | 10 mg; 100 mg |
| N6-Benzoyl-8-benzyloxy-2'-deoxyadenosine | PR 3230 | ≥95% | 50 mg; 250 mg |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-8-oxo-2'-deoxyadenosine | PR 3260 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| 8-Benzyloxy-2'-deoxyadenosine | PR 3280 | ≥97% | 100 mg; 1 g |
| 8-Bromo-2'-deoxyadenosine | PR 3290 | ≥90% | 2 g; 10 g |
| 8-Bromo-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3320 | ≥95% | 100 mg; 1 g |
| 8-Bromo-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3340 | ≥97% | 0g (discontinued); |
| 2'-Deoxyadenosine Monohydrate | PR 3445 | ≥97% | 25 g; 100 g |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2-Fluoro-2'-deoxyadenosine | PR 3496 | ≥97% | 25 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| N6-Methyl-2'-deoxyadenosine | PR 3740 | ≥97% | 100 mg; 1 g |
| 4-Chloro-1-(2-deoxy-β-D-ribofuranosyl)-7-methyl-1H-imidazo[4,5-c]pyridine | PRA 10012 | ≥95% | 10 mg; 50 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| 7-(3-Nitrophenyl)-7-deaza-2'-deoxyadenosine | PRA 10032 | ≥95% | 10 mg; 50 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 8-Allyloxy-2'-deoxyguanosine | PR 3010 | ≥90% | 0Discontinued; |
| 8-Allyloxy-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3015 | ≥90% | 1 g; 10 g |
| 8-Allyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3020 | ≥90% | 1 g; 10 g |
| 5'-Azido-5'-deoxyguanosine | PR 3225 | ≥90% | 5 mg; 10 mg |
| 8-Benzyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3285 | ≥90% | 1 g; 10 g |
| 8-Bromo-2'-deoxyguanosine | PR 3300 | ≥90% | 1 g; 5 g |
| 8-Bromo-5'-O-(dimethyoxytrityl)-N2-(dimethyl-aminomethylidene)-2'-deoxyguanosine | PR 3310 | ≥97% | 500 mg; 1 g |
| 8-Bromo-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3330 | ≥90% | 250 mg; 1 g |
| 5'-O-Dimethoxytrityl-N2-(dimethylaminomethylidene)-8-ethenyl-2'-deoxyguanosine | PR 3335 | ≥95% | 100 mg; 1 g |
| 2'-Deoxyguanosine monohydrate | PR 3452 | ≥97% | 10 g; 100 g |
| α-2'-Deoxyguanosine | PR 3455 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-ethyl-2'-deoxyguanosine | PR 3600 | ≥97% | 100 mg; 1 g |
| 3',5'-Di-O-acetyl-2'-deoxyguanosine | PR 3605 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-N2-methyl-2'-deoxy-guanosine | PR 3630 | ≥97% | 100 mg; 1 g |
| N2-Ethyl-2'-deoxyguanosine | PR 3700 | ≥95% | 25 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| N2-Isobutyl-2'-deoxyguanosine | PR 3745 | ≥97% | 10 mg; 100 mg |
| N1-Methyl-2'-deoxyguanosine | PR 3748 | ≥97% | 25 mg; 1 g |
| N2-Methyl-2'-deoxyguanosine | PR 3750 | ≥97% | 25 mg; 100 mg |
| O6-Methyl-2'-deoxyguanosine | PR 3755 | ≥90% | 5 mg; 25 mg |
| 6-Thio-2'-deoxyguanosine | PR 3845 | ≥97% | 10 mg; 100 mg |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 2'-O-Methyladenosine | PR 3734 | ≥97% | 1 g; |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-thiouridine | PY 7575 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-(methylithio)uridine | PY 7577 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 5'-O-Acetyl-3'-azido-N2-palmitoyl-2',3'-dideoxy-guanosine | PR 3000 | ≥97% | 25 mg; 250 mg |
| 3'-Azido-N6-benzoyl-2',3'-dideoxyadenosine | PR 3200 | ≥90% | 50 mg; 250 mg |
| 3'-Azido-2',3'-dideoxyadenosine | PR 3210 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-2',3'-dideoxyguanosine | PR 3220 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| N6-Benzoyl-3'-deoxyadenosine | PR 3240 | ≥97% | 100 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-3'-deoxyadenosine | PR 3250 | ≥97% | 100 mg; 1 g |
| 3'-Deoxyadenosine | PR 3430 | ≥97% | 10 mg; 100 mg |
| 3'-Deoxyguanosine | PR 3460 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-3'-deoxyguanosine | PR 3590 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-3'-deoxyguanosine | PR 3690 | ≥97% | 20 mg; 100 mg |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 5'-O-(Dimethoxytrityl)-5,6-dihydro-2'-deoxyuridine | PY 7230 | ≥97% | 100 mg; |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 2-Amino-6-chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3040 | ≥97% | 1 g; |
| 2-Amino-6-chloro-9-(3,5-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3045 | ≥95% | 1 g; |
| 2-Amino-6-chloro-9-(β-D-ribofuranosyl)purine | PR 3050 | ≥95% | 5 g; 25 g |
| 6-Chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3370 | ≥97% | 100 mg; 1 g |
| 6-Chloro-9-(3,5-O-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3380 | ≥90% | 100 mg; 1 g |
| 6-Chloro-9-(5-O-dimethoxytrityl-β-D-2-deoxyribofuranosyl)purine | PR 3390 | ≥97% | 0 g; |
| 6-Chloro-9-(β-D-ribofuranosyl)purine | PR 3400 | ≥97% | 5 g; 10 g |
| Adenosine | PR 3005 | ≥97% | 100 g; 1 kg |
| 8-Methyladenosine | PR 3007 | ≥95% | 25 mg; 100 mg |
| Vidarabine | PR 3008 | ≥97% | 1 g; 5 g |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| N1-Methyladenosine hydroiodide | PR 3032 | ≥95% | 100 mg; 1 g |
| 2-Methyladenosine | PR 3035 | ≥97% | 10 mg; 25 mg |
| 5'-Chloro-5'-deoxyadenosine | PR 3360 | ≥97% | 100 mg; 1 g |
| N6-Methyladenosine | PR 3732 | ≥97% | 100 mg; 1 g |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 2-Amino-4-chloro-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10000 | ≥97% | 100 mg; 1 g |
| 2-Amino-4-methoxy-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10005 | ≥97% | 500 mg; 1 g |
| 4-Chloro-1-(β-D-2-deoxyribofuranosyl)imidazo[4,5-C]pyridine | PRA 10006 | ≥90% | 25 mg; 100 mg |
| 8-Azaadenosine | PRA 10007 | ≥97% | 20 mg; |
| 8-Aza-7-deaza-2'-deoxyadenosine (4-Amino-1-(2-deoxyribofuranosyl)pyrazolo[3,4-d]-pyrimidine) | PRA 10008 | ≥95% | 10 mg; 100 mg |
| 4-Chloro-1-(3,5-di-O-toluoyl-2-deoxy-β-D-ribofuranosyl)pyrazolo[3,4-d]pyrimidine | PRA 10009 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-7-deaza-2'-deoxyadenosine | PRA 10010 | ≥97% | 100 mg; 1 g |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; 1 g |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-7-deaza-2'-deoxyadenosine | PRA 10020 | ≥97% | 100 mg; 1 g |
| 3-Deaza-2'-deoxyadenosine | PRA 10025 | ≥97% | 25 mg; 100 mg |
| 7-Deaza-2'-deoxyadenosine | PRA 10030 | ≥97% | 100 mg; 1 g |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 7-Deaza-2'-deoxyguanosine | PRA 10040 | ≥97% | 100 mg; 1 g |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 7-Deaza-2'-deoxyxanthosine | PRA 10050 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-7-deaza-2'-deoxyxanthosine | PRA 10055 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10100 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10110 | ≥97% | 100 mg; 1 g |
| Sangivamycin | PRA 10140 | ≥97% | 10 mg; 25 mg |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; 100 mg |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| dNaM | FC 8110 | ≥97% | 25 mg; 100 mg |
| 9-Deaza-2'-deoxyguanosine | PRA 10120 | ≥97% | 10 mg; 100 mg |
| 9-Deazaguanosine | PRA 10130 | ≥97% | 10 mg; 100 mg |
| 2-Chloro-6-(β-D-2-deoxyribofuranosyl)-3,5-diaminopyrazine | PYA 11000 | ≥97% | 10 mg; 25 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| 2'-Deoxypseudoisocytidine | PYA 11005 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudouridine | PYA 11010 | Purity: ≥97% | 25 mg; |
| 5'-O-(Dimethoxytrityl)-N-(dimethylamino) methylidene-2'-deoxypseudoisocytidine | PYA 11035 | Purity: ≥97% | 50 mg; 100 mg |
| 1,3-Dimethyl-2'-deoxypseudouridine | PYA 11040 | ≥97% | 10 mg; 100 mg |
| 1,3-Dimethylpseudouridine | PYA 11050 | ≥97% | 10 mg; 50 mg |
| N1-Methylpseudouridine | PYA 11052 | ≥95% | 10 mg; 50 mg |
| N3-Methylpseudouridine | PYA 11054 | ≥97% | 10 mg; 25 mg |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Pseudoisocytidine hydrochloride | PYA 11060 | ≥97% | 10 mg; 100 mg |
| Pseudothymidine | PYA 11070 | ≥97% | 10 mg; 100 mg |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; 50 mg |
| 3'-O-(t-Butyldimethylsilyl)-5'-oxo-2'-deoxy-8,5'-cycloadenosine | PR 3350 | ≥97% | 10 mg; |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-Deoxy-8,5'-cycloadenosine | PR 3440 | ≥97% | 10 mg; 100 mg |
| 2',5'-Dideoxy-8,5'-cycloadenosine | PR 3500 | ≥97% | 10 mg; |
| 2',3'-O-Isopropylidene-5'-oxo-8,5'-cycloadenosine | PR 3730 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-8,5'-cycloadenosine | PR 3800 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-2'-deoxy-8,5'-cycloadenosine | PR 3810 | ≥97% | 10 mg; |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5-(furan-2-yl)-2'-deoxycytidine | PY 7054 | ≥97% | 25 mg; 100 mg |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 5-Bromo-2'-deoxycytidine | PY 7115 | ≥97% | 1 g; 10 g |
| Cytidine | PY 7215 | ≥97% | 50 g; 500 g |
| 2'-Deoxycytidine | PY 7216 | ≥97% | 10 g; 50 g |
| 2'-Deoxycytidine Hydrochloride | PY 7217 | ≥97% | 5 g; 50 g |
| 5'-Azido-2',5'-dideoxycytidine | PY 7219 | ≥97% | 25 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| N4-Ethyl-2'-deoxycytidine | PY 7245 | ≥97% | 100 mg; 250 mg |
| 5-Methyl-2'-deoxyisocytidine | PY 7255 | ≥95% | 500 mg; 1 g |
| 6-(β-D-2-Deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7270 | ≥97% | 20 mg; 50 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 6-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7380 | ≥97% | 50 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5-O-(Dimethoxytrityl)-N4-dimethylaminomethylidene-5-iodo-2'-deoxycytidine | PY 7410 | ≥97% | 100 mg; |
| 6-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido[4,5-c][1,2]oxazin-7-one | PY 7540 | ≥95% | 250 mg; 500 mg |
| Cytidin-5-yl-methanesulfonate sodium salt hydrate | PY 7586 | ≥95% | 50 mg; 100 mg |
| 5-[(2-Cyanoethoxy)methyl]-2'-deoxycytidine | PY 7587 | ≥97% | 10 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxycytidine | PY 7588 | ≥97% | 50 mg; 100 mg |
| 5-Formyl-2'-deoxycytidine | PY 7589 | ≥97% | 5 mg; 10 mg |
| 5-Carboethoxy-2'-deoxycytidine | PY 7592 | ≥95% | 25 mg; 100 mg |
| 2'-Deoxycytidine-5-carboxylic acid, sodium salt | PY 7593 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxymethylcytidine | PY 7596 | ≥97% | 50 mg; 100 mg |
| Cytidine-5-carboxylic acid, sodium salt | PY 7598 | ≥97% | 10 mg; 50 mg |
| 5-Formylcytidine | PY 7599 | ≥97% | 5 mg; 10 mg |
| 5-Iodo-2'-deoxycytidine | PY 7607 | ≥97% | 2 g; 10 g |
| 5-Iodocytidine | PY 7609 | ≥97% | 5 g; |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Methyl-2'-deoxycytidine Hydrochloride | PY 7635 | ≥97% | 0.25 g; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methylcytidine | PY 7637 | ≥97% | 1 g; 5 g |
| N4-Methylcytidine | PY 7638 | ≥97% | 25 mg; 100 mg |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 2-Thiocytidine | PY 7721 | ≥97% | 10 mg; 100 mg |
| 2-Thio-2'-deoxycytidine | PY 7723 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| 8-Hydroxyguanosine | PR 3795 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 5-Aza-2'-deoxycytidine | PY 7105 | ≥95% | 25 mg; 100 mg |
| 5,6-Dihydro-5-aza-2'-deoxycytidine | PY 7106 | ≥97% | 25 mg; 100 mg |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| Nap-dU | PY 7735 | ≥97% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 8-18O-Hydroxyguanosine | IOPR 3795 | ≥95% | 2 mg; 5 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| N2-Dimethylguanosine | PR 3702 | ≥97% | 10 mg; 100 mg |
| Guanosine | PR 3703 | ≥97% | 100 g; 500 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| O6-Methylguanosine | PR 3757 | ≥97% | 25 mg; 100 mg |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 8-Bromoguanosine | PR 3796 | ≥97% | 0 g; |
| 8-Benzyloxyguanosine | PR 3797 | ≥95% | 100 mg; 1 g |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 2'-Deoxy-4-desmethylwyosine | PR 3450 | ≥95% | 100 mg; 500 mg |
| 2'-Deoxyinosine | PR 3463 | ≥97% | 10 g; 100 g |
| 5'-Azido-2',5'-dideoxyinosine | PR 3464 | ≥97% | 5 mg; 25 mg |
| 3',5'-Di-O-acetyl-2'-deoxyinosine | PR 3480 | ≥97% | 1 g; |
| 3',5'-Di-O-acetyl-O6-phenyl-2'-deoxyinosine | PR 3490 | ≥90% | 1 g; |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| 5'-O-(Dimethoxytrityl)-O6-phenyl-2'-deoxyinosine | PR 3660 | ≥97% | 100 mg; 1 g |
| Inosine | PR 3725 | ≥97% | 100 g; 500 g |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| O6-Phenyl-2'-deoxyinosine | PR 3840 | ≥97% | 100 mg; 1 g |
| 2-Fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3842 | ≥97% | 25 mg; |
| 5'-O-Dimethoxytrityl-2-fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3843 | ≥90% | 25 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| N6-(Diisobutylaminomethylidene)-2'-deoxyisoguanosine | PR 3510 | ≥90% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3520 | ≥95% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3530 | ≥90% | 100 mg; 1 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| d5SICS | FC 8120 | ≥97% | 25 mg; 100 mg |
| AICA Riboside (AICAR) | MN 20001 | ≥97% | 0 g (DISCONTINUED); |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 2,6-Bis-O-[2-(4-nitrophenyl)ethyl]-2'-deoxyxanthosine | PR 3692 | ≥95% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| tC Nucleoside | PYA 11110 | ≥97% | 50 mg; 100 mg |
| tCnitro Nucleoside | PYA 11115 | ≥95% | 5 mg; 25 mg |
| 2'-Deoxynebularine | PR 3470 | Purity: ≥97% | 100 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-3-nitropyrrole | PYA 11020 | ≥97% | 50 mg; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3-nitropyrrole | PYA 11030 | ≥95% | 100 mg; |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; |
| 5'-Amino-5'-deoxythymidine | PY 7030 | ≥97% | 25 mg; 50 mg |
| O2,5'-Anhydrothymidine | PY 7060 | ≥95% | 500 mg; 1 g |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 5'-Azido-5'-deoxythymidine | PY 7070 | ≥97% | 25 mg; 100 mg |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-O-(t-Butyldimethylsilyl)-5'-deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7120 | ≥97% | 1 g; |
| 3'-O-(t-Butyldimethylsilyl)thymidine | PY 7130 | ≥95% | 500 mg; 1 g |
| 5'-O-(t-Butyldimethylsilyl)thymidine | PY 7140 | ≥97% | 5 g; 10 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)thymidine | PY 7150 | ≥97% | 1 g; 5 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)-O4-(2,4,6-triisopropylphenylsulfonyl)thymidine | PY 7160 | ≥95% | 100 mg; 500 mg |
| S4-(2-Cyanoethyl)-5'-O-(dimethoxytrityl)-4-thiothymidine | PY 7200 | ≥95% | 10 mg; 100 mg |
| S4-(2-Cyanoethyl)-4-thiothymidine | PY 7210 | ≥95% | 10 mg; 100 mg |
| 5'-Deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7250 | ≥97% | 1 g; |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 1-(3,5-Di-O-acetyl-β-D-deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)-5-methylpyrmidin-2-one | PY 7315 | ≥90% | 1 g; 10 g |
| 2',3'-Didehydro-3'-deoxythymidine | PY 7328 | ≥95% | 10 mg; 100 mg |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| 5'-O-(Dimethoxytrityl)-N3/O4-(toluoyl)-2-thiothymidine | PY 7510 | ≥97% | 50 mg; 100 mg |
| 2-O-Ethylthymidine | PY 7561 | ≥97% | 500 mg; 1 g |
| 5'-Iodo-5'-deoxythymidine | PY 7610 | ≥97% | 250 mg; 1 g |
| 5'-O-Methylthymidine | PY 7680 | ≥95% | 50 mg; 100 mg |
| 2-Thiothymidine | PY 7725 | ≥95% | 20 mg; 100 mg |
| Thymidine | PY 7727 | ≥97% | 25 g; 250 g |
| 5'-O-(p-Toluenesulfonyl)thymidine | PY 7740 | ≥97% | 5 g; |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5'-Trifluoroacetamido-5'-deoxythymidine | PY 7750 | ≥97% | 50 mg; |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 6-Azathymidine | PYA 11058 | ≥95% | 25 mg; 100 mg |
| NPOM-Caged-dT CEP | BA 0317 | ≥95% | 100 µmol; 0.25 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 5-Ethynyl uridine CEP | BA 0353 | ≥90% | 100 µmol; 0.25 g |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 5-(Furan-2-yl)-2'-deoxyuridine | PY 7053 | ≥97% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)pyrimidin-2-one | PY 7055 | ≥97% | 20 mg; 100 mg |
| 5-Bromo-2'-deoxyuridine | PY 7117 | ≥97% | 10 g; 25 g |
| 5-Bromouridine | PY 7118 | ≥95% | 5 g; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carbomethoxyvinyl)uridine | PY 7172 | ≥97% | 25 mg; 250 mg |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)uridine | PY 7185 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| S4-(2-Cyanoethyl)-4-thio-2'-deoxyuridine | PY 7212 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 2'-Deoxyuridine | PY 7275 | ≥97% | 25 g; 100 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-deoxyuridine | PY 7280 | ≥95% | 100 mg; 500 mg |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7310 | ≥97% | 20 mg; 50 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-deoxyuridine | PY 7450 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5-Methoxymethyl-2'-deoxyuridine | PY 7465 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-Ethynyl-2'-deoxyuridine | PY 7562 | ≥97% | 25 mg; 100 mg |
| 5-Ethynyl uridine | PY 7563 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-deoxyuridine | PY 7565 | ≥97% | 100 mg; 1 g |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7580 | ≥97% | 25 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7590 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Acetoxymethyl-2'-deoxyuridine | PY 7604 | ≥97% | 25 mg; 100 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 2'-Fluoro-5'-iodo deoxyuridine | PY 7612 | ≥95% | 100 mg; |
| 5-Iodo-2'-deoxyuridine | PY 7615 | ≥97% | 10 g; 25 g |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 5-Iodouridine | PY 7632 | ≥95% | 5 g; 25 g |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 3-Methyluridine | PY 7694 | ≥97% | 25 mg; 100 mg |
| 5-Methyluridine | PY 7695 | ≥97% | 200 mg; 1 g |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 5-(Propargyloxy)-2'-deoxyuridine | PY 7712 | ≥95% | 10 mg; 100 mg |
| Zebularine | PY 7715 | ≥97% | 10 mg; 25 mg |
| 3',5'-O-(1,1,3,3-Tetraisopropyl-1,3-disiloxanediyl)-2'-deoxyuridine | PY 7720 | ≥90% | 500 mg; 1 g |
| 2-Thiouridine | PY 7724 | ≥97% | 25 mg; 100 mg |
| 5'-O-(p-Toluenesulfonyl)-2'-deoxyuridine | PY 7730 | ≥97% | 1 g; 5 g |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[3-(Trifluoroacetamido)-1-(E)-propenyl]uridine | PY 7758 | ≥97% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| 5-[N-(6-(Trifluoracetamido)hexyl)-(E)-acrylamido]uridine | PY 7775 | ≥97% | 100 mg; 1 g |
| Uridine | PY 7780 | ≥97% | 100 g; 500 g |
| 2'3'-O-Isopropylidene uridine | PY 7781 | ≥97% | 5 g; 25 g |
| 5-Hydroxymethyl uridine | PY 7782 | ≥97% | 50 mg; 100 mg |
| 5-Methoxyuridine | PY 7783 | ≥97% | 10 mg; 50 mg |
| 6-Aza-2'-deoxyuridine | PYA 11057 | ≥95% | 50 mg; 100 mg |
" data-original="http://bioauxilium.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Berry & Associates全系列修饰核苷酸"> 艾美捷科技代理Berry & Associates全系列修饰核苷酸

MoBiTec公司位于德国Göttingen,成立于1987年,致力于为细胞和分子生物学领域提供创造性的工具产品。
MoBiTec公司产品涵盖two- & one-hybrid systems、a phagemid display system、convenient Lambda PS genomic libraries、kits for efficient expression and purification of recombinant proteins、cell transfection reagents and cell culture tools、immobilized and soluble enzymes, many products for genomics and proteomics research, numerous antibodies, cytokines, growth factors and recombinant proteins, superior fluorescence reagents and kits.
MoBiTec的主要产品包括:
(1)Vector Systems
Bacillus Expression Systems
Lactococcus Expression Systems
Yeast Expression Systems等
(2)Genomics
Nucleic Acid Purifcation and Isolation
CRISPR/Cas9 Genome Editing
Magnetic Beads DNA Tools等
(3)Proteomics
Gel Staining, Quantitation and
Western Blots
Magnetic Beads等
(4)Antibodies and Peptides
Antibody Database Search
Primary Antibodies
Secondary Antibodies等
(5)Fluorescence Technology
Fluorescent Dyes
Fluorometric Assays
Fluorescent Indicator Dyes等
(6)Cell Biology
Transfection
Electroporation
Cells and Cell Culture Media等
Glycobiology
Carbohydrates from Dextra
Glycoassays from Sumitomo等
(7)Interaction Screening
Two- and One Hybrid Systems
Phagemid Display
RNA/Protein Interaction and Protein/Protein Interaction等
(8)In Vitro Diagnostics and Assays
Cell Viability, Proliferation and Function
Infectious Serology
Disease Monitoring等
(9)Lab Supplies
Mobicols and Plastic Columns
Microscopy Accessories
Plastic Supply等
(10)Chemicals and Buffers
Additives
Media and Components
Western Blotting and ELISA等
(11)Customized Services
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
" data-original="http://bioauxilium.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="MoBiTec"> MoBiTec
Dianova公司为德国著名的病理免疫组化产品供应商,具备领先的抗体制备工艺及严格的质控系统,产品在国际上享有良好的声誉。
Since its foundation in 1982, dianova GmbH provides professionals in Life Sciences with antibodies, immunoassays, and products for molecular biology. More than 30 years of grown expertise give rise to a fundamental knowledge about biochemical applications and a profound understanding of customer needs in research and routine diagnostic laboratories of universities, hospitals and the pharmaceutical industry.
Dianova公司的主要产品包括:
Proteine
Assays / Kits
Reagenzien / Medien
Material
Geräte
Antikörper-Service
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
" data-original="http://bioauxilium.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Dianova"> Dianova
<艾美捷科技代理Akina品牌全系列产品
Akina, Inc. 于2001年成立,是一家具有多年经营历史的公司,PolyScitech作为其旗下部门,依托公司的资源和平台开展业务。由Kinam Park博士创立,他是普渡大学生物医学工程与药剂学教授。Kinam Park博士在相关学术领域具有深厚的造诣和丰富的经验,这为PolyScitech部门在技术研发和专业方向上提供了坚实的学术支持和引领。Akina公司的产品线包括:PolySciTech Polymers、PURASORB® Polymers、Viatel™m Polymers、VIVOS™ PLGA-g-PEG、PLGA/PLA Standards、NuPlonTm、AquaGel@ Hydrogels、PET Prepolymer、Flamma Fluor Fluorescent Dyes、Kitopure Chitosan、3DCellMaker。
Akinalytics作为Akina, Inc.的部门,专门从事控释药物输送系统以及可生物降解聚合物及其制药/生物医学应用。提供快速周转和具有竞争力的价格的样品分析,包括FTIR分光光度法、紫外/可见分光光度法、GPC、调制差示扫描量热法、流变分析、机械/纹理分析、光学分析等。

▍Akina公司产品线
● PolySciTech Polymers:提供各种类型的聚合物产品,广泛应用于科研和工业领域
● PURASORB® Polymers:由于Corbion和Akina, Inc. (PolySciTech) 之间的分销关系,Purasorb®聚合物现作为研究产品提供,简化开发项目。用于长效注射剂、医疗器械等,为GMP制造的产品提供临床转化的直接途径。
● Viatel™ Polymers:精选开发产品,得益于Ashland和Akina, Inc. (PolySciTech) 之间的分销关系。无最低订购量要求,购买时间快,便利开发需求。
● VIVOS™ PLGA-g-PEG:使用聚丙交酯-乙醇共聚酯-接枝-聚乙二醇组成的快速溶解、可生物降解的热凝胶输送活性药物。由Vivos, Inc.和Akina, Inc.合作开发,简化药物递送开发。
产品应用:这些聚合物产品具有多种应用,包括但不限于阴离子药物/核酸衍生物的递送;纳米通道和纳米孔的形成;形成“隐形”聚乙二醇化微粒;聚合物混合物的塑化(不溶性);用于改性/交联的短链树脂;热凝胶化;药物的水溶性
▍Akina部分产品列表
<| 货号 | 品名 | 规格 | Mw |
| AK001 | Methoxy poly(ethylene glycol)-b-poly(caprolactone) | 5g;10g;25g | ~2,000:5,200 Da |
| AK002 | Methoxy poly(ethylene glycol)-b-poly(lactide-co-glycolide) | 5g;10g;25g | ~2,000:4,110 Da |
| AK003 | Methoxy poly(ethylene glycol)-b-poly(L-lactide) | 5g;10g;25g | ~2,000:1,700 Da |
| AK004 | Methoxy poly(ethylene glycol)-b-poly(L-lactide) | 5g;10g;25g | ~2,000:5,000 Da |
| AK005 | Methoxy poly(ethylene glycol)-b-poly(L-lactide) | 5g;10g;25g | ~2,000:10,000 Da |
| AK006 | Methoxy poly(ethylene glycol)-b-poly(L-lactide) | 5g;10g;25g | ~750:5,600 Da |
| AK007 | Methoxy poly(ethylene glycol)-b-poly(L-lactide) | 5g;10g;25g | ~5,000:4,900 Da |
| AK008 | Poly(L-lactide)-b-poly(ethylene glycol)-b-poly(L-lactide) | 5g;10g;25g | ~2,400:2,000:2,400 Da |
| AK009 | Methoxy poly(ethylene glycol)-b-poly(D,L-lactide) | 5g;10g;25g | ~2,000:2,200 Da |
| AK010 | Methoxy poly(ethylene glycol)-b-poly(lactide-co-glycolide) | 5g;10g;25g | ~5,000:10,000 Da |
| AK011 | Poly(lactide-co-glycolide)-b-poly(ethylene glycol)-b-poly(lactide-co-glycolide) | 5g;10g;25g | ~1,600:1,000:1,600 Da |
| AK012 | Poly(lactide-co-glycolide)-b-poly(ethylene glycol)-b-poly(lactide-co-glycolide) | 5g;10g;25g | ~1,000:1,000:1,000 Da |
| AK013 | Poly(lactide-co-glycolide)-b-poly(ethylene glycol)-b-poly(lactide-co-glycolide) | 5g;10g;25g | ~2,000:400:2,000 Da |
| AK014 | Poly(lactide-co-glycolide)-b-poly(ethylene glycol)-b-poly(lactide-co-glycolide) | 5g;10g;25g | ~400:400:400 Da |
| AK015 | Poly(lactide-co-glycolide)-b-poly(ethylene glycol)-b-poly(lactide-co-glycolide) | 5g;10g;25g | ~5,000:1,000:5,000 Da |
| AK016 | Poly(lactide-co-glycolide)-b-poly(ethylene glycol)-b-poly(lactide-co-glycolide) | 5g;10g;25g | ~70,000:4,600:70,000 Da |
| AK019 | Poly(lactide-co-glycolide)-b-poly(ethylene glycol)-b-poly(lactide-co-glycolide) | 5g;10g;25g | ~1,500:1,500:1,500 Da |
| AK021 | Methoxy poly(ethylene glycol)-b-poly(D,L-lactide) | 5g;10g;25g | ~5,000:50,000 Da |
| AK023 | Methoxy poly(ethylene glycol)-b-poly(lactide-co-glycolide) | 5g;10g;25g | ~2,000:1,500 Da |
| AK024 | Poly(lactide-co-glycolide)-b-poly(ethylene glycol)-b-poly(lactide-co-glycolide) | 5g;10g;25g | ~1,100:1,000:1,100 Da |
| AK025 | Methoxy poly(ethylene glycol)-b-poly(L-lactide) | 5g;10g;25g | ~750:1,000 Da |
| AK026 | Methoxy poly(ethylene glycol)-b-poly(lactide-co-glycolide) | 5g;10g;25g | ~5,000:55,000 Da |
| AK027 | Methoxy poly(ethylene glycol)-b-poly(lactide-co-glycolide) | 5g;10g;25g | ~2,000:15,000 Da |
| AK028 | Poly(lactide-co-caprolactone)-b-poly(ethylene glycol)-b-poly(lactide-co-caprolactone) | 5g;10g;25g | ~5,700:4,600:5,700 Da |

RayBiotech is a leading life sciences company providing proteomic discovery tools. RayBiotech has nearly 150 employees whose objectives are to provide excellent products and service worldwide to RayBiotech customers which include scientists in industry, academic and research institutes in 41 countries. RayBiotech is committed to accelerating customer success through innovation and leadership in the Life Sciences.
RayBiotech公司致力于开发、研制、生产及销售以抗体芯片、ELISA/EIA、抗原抗体为主的酶免产品,不仅拥有强大的技术团队,其中40%博士及博士后学历,而且十分重视产品的科技创新,公司先后与哈佛大学、普林斯顿大学等国际多家权威科研机构、院校紧密合作,将技术进行广泛应用。世界各国众多科学家使用了RayBiotech的抗体芯片等酶免产品已发表数千篇文献在Nature、Nature Medicine、Cell、PNAS、Lancet 等世界顶级期刊上。客户对RayBiotech芯片技术和产品的质量都给予了肯定和很高的评价。以抗体芯片生产为核心,RayBiotech公司将生产线扩大到ELISA/EIA、抗原抗体等数万种产品,涵盖了免疫学领域大多数主要产品种类。经过10余年的发展和品牌积累,RayBiotech已成为国际上公认的蛋白芯片的先驱企业,抗体及酶免产品专家。
RayBiotech公司的主要产品包括:
(1)Arrays
Antibody Arrays
Glycobiology Arrays
Protein Arrays
Phosphorylation Arrays
(2)ELISA Kits
Sandwich ELISA Kits
EIA Kits
Transcription Factor Activity Assay Kits
Phosphorylation ELISA Kits
Post-Translational Modification ELISA Kits
Cell-Based Phosphorylation ELISA Kits
SpeedELISA Kits
IQELISA Kits
(3)Functional Assays
Cell Viability Assays
Lipid Transfer Assays
Luciferase Assays
Molecular Biology Assays
Oxidative Stress Assays
Phosphorylation Assays
Apoptosis Assays
Cytotoxicity Assays
Metabolism Assays
(4)Reagents
Antibodies
Proteins
Supplemental Reagents
(5)Flow Cytometry
Flow Cytometry Antibodies
Live/Dead Markers
Intracellular Staining Kits
(6)Other Products
Lab Equipment
Isotyping
Software
Cell Fractionation Kits
Protein Quantification
Magnetic Beads
Blood Collection
Kit Components
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
" data-original="http://bioauxilium.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="RayBiotech"> RayBiotech地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:18372041646
传真:13212737804
邮箱:sales@amyjet.com
0.3158